Relaxing incisions reduce postop astigmatism

Article

Relaxing incisions are a safe and effective method for reducing postoperative astigmatism and help improve visual acuity (VA), according to a study published in the March issue of the Journal of Refractive Surgery.

Relaxing incisions are a safe and effective method for reducing postoperative astigmatism and help improve visual acuity (VA), according to a study published in the March issue of the Journal of Refractive Surgery.

Margareta Claesson, MD and John Armitage, PhD, from the Sahlgrenska University Hospital, Sweden and the University of Bristol, UK, respectively, conducted a study to determine the impact of relaxing incisions for correcting postoperative astigmatism following penetrating keratoplasty.

Data was collected through the Swedish Corneal Transplant Register and, of the 1,161 grafts with complete two-year follow-up, 131 underwent relaxing incisions. Stepwise multiple regression was used to determine the factors that influenced the extent of astigmatism. The change in astigmatism brought about by relaxing incisions was evaluated by subtraction and vector analysis.

In patients who underwent relaxing incisions, astigmatism was reduced from 8.40 D to 3.80 D. The mean difference by subtraction was 4.50 D and vector analysis showed the overall reduction of astigmatism induced by surgery to be 7.90 D. Compared with grafts with no refractive surgery, a trend was seen that suggested corrected VA was improved following relaxing incisions.

It was concluded that relaxing incisions are safe and effective as a method of reducing postoperative astigmatism and may even help improve VA in some cases.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.